Clinical Trials List
2016-06-01 - 2019-12-31
Phase I
Terminated4
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 陳冠宇 Division of General Internal Medicine
- 廖斌志 Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- Chong-Jen Yu Division of General Internal Medicine
- 廖唯昱 Division of General Internal Medicine
- 張端瑩 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of General Internal Medicine
- Jih-Hsiang Lee Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- YEN-SHEN LU Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 蔡鎮良 Division of Thoracic Medicine
- 陳佳宏 Division of Hematology & Oncology
- 陳宇欽 Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- 吳宜穎 Division of Hematology & Oncology
- 彭萬誠 Division of Thoracic Medicine
- 黃子權 Division of Hematology & Oncology
- 沈志浩 Division of Thoracic Medicine
- 戴明燊 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Tsu-Yi Chao Division of Hematology & Oncology
- kang-Yun LEE Division of Thoracic Medicine
- 蘇勇誠 Division of Hematology & Oncology
- Wei-Hwa Lee Division of Others -
- Wei-Hong Cheng Division of Hematology & Oncology
- TSU-YI CHAO Division of Hematology & Oncology
- Yao-Yu Hsieh Division of Hematology & Oncology
- Po-Hao Feng Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
2 Terminated
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
75 participants